BioSpace News Archive

Artelo Biosciences, Inc. (NASDAQ: ARTL), announced today that it has selected Aptus Clinical Ltd. (Aptus), a specialist Clinical Contract Research Organization based in the United Kingdom (UK) with particular expertise in oncology, rare diseases and advanced therapies, as its contract research organization (CRO) for the Company’s planned Phase 1b/2a

CEM Corporation announced that it has entered into a definitive agreement to purchase the instrumentation lines of Intavis Bioanalytical Instruments AG, with headquarters in Cologne, Germany.

Dr. Hassig will oversee Boundless Bio’s drug discovery efforts, grow the company’s research team, and guide the company in building out a pipeline of ecDNA-targeting therapeutics.

Technology Provides Pregnant Women Widespread NIPT Access

SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that results from its U.S. pilot Investigational Device Exemption (IDE) study in rheumatoid arthritis (RA) have been accepted for oral presentation at the American College of Rheumatology (ACR) Annual Meeting, being held November 8-13, 2019 in Atlanta, GA

Award recognizes the innovative use of Hyland’s Perceptive Content application to digitize maltreatment investigation processes

Astia, the global organization that levels the investment playing field for startups that include women leaders, today announced the appointment of nVision Medical founder and CEO, Surbhi Sarna, to its Board of Directors.

Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the third quarter 2019 on Tuesday, Nov. 5 at 9 a.m. ET. The company will issue a news release detailing its results before the market opens that same day.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the Company will release its third quarter financial results on Tuesday, November 5, 2019, after the close of US markets.

Phio Pharmaceuticals Corp. announced that several posters featuring INTASYL™ will be presented at the Society for Immunotherapy of Cancer 2019 Annual Meeting, held November 6-10 at the Gaylord National Hotel and Convention Center in National Harbor, MD.